Previous studies have shown that CA3, a novel YAP1/TEAD4 transcriptional activity inhibitor, targets cancer stem cells in esophageal adenocarcinoma and mesothelioma [15, 16]. The gene discussed is TEAD4; the disease is esophageal adenocarcinoma.